© Springer International Publishing AG 2017Robert M. Hoffman (ed.)Patient-Derived Mouse Models of Cancer Molecular and Translational Medicinehttps://doi.org/10.1007/978-3-319-57424-0_2 2. The Revival of Patient-Derived Xenograft Mouse Models of Cancer: Way Back to the Future Robert M. Hoffman1, 2 …
Fig. 10.1 Drug-efficacy testing in the PDOX model. PDOX nude mice were treated with saline, carboplatin, trastuzumab + lapatinib, trastuzumab + lapatinib + entinostat, or entinostat alone. (a) Bar graphs…
The athymic “nude” mouse is possibly the most important tool in cancer research. The nude mouse has enabled the studies of human cancer in the laboratory in vivo. Nude mice…
© Springer International Publishing AG 2017Robert M. Hoffman (ed.)Patient-Derived Mouse Models of Cancer Molecular and Translational Medicinehttps://doi.org/10.1007/978-3-319-57424-0_7 7. The First Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer: Cancer of the Colon, Pancreas, Lung,…
© Springer International Publishing AG 2017Robert M. Hoffman (ed.)Patient-Derived Mouse Models of Cancer Molecular and Translational Medicinehttps://doi.org/10.1007/978-3-319-57424-0_6 6. Techniques for Surgical Orthotopic Implantation of Human Tumors to Immunodeficient Mice Robert M. Hoffman1, 2 (1) AntiCancer, Inc.,…
Fig. 7.1 The JAK-STAT signalling pathway. Upon binding to the membrane receptors, cytokines initiate downstream signalling cascades through the JAK-STAT pathway. Cytokine receptor homodimers or heterodimers phosphorylate and activate JAKs,…
Fig. 8.1 DNA mismatch errors commonly occur at unstable genomic regions with multisatellite repeats. The repair of such DNA mismatch errors is the function of the MMR system. This process…
Fig. 3.1 Cancer vaccination and induction of T cell activation Vaccine Platforms and Vectors Common Mechanisms of Action This section will discuss various therapeutic cancer vaccine constructs, including peptide, DNA,…
Phase Regimen Patient population Results I Pembrolizumab (anti-PD-1 antibody) Advanced solid tumours, including oesophageal cancer ORR: 30.4 % (29.4 % in squamous cell carcinoma vs. 40 % in adenocarcinoma); 12-month…
